Skip to main content
SpringerLink
Log in

Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Eighteen previously untreated patients with metastatic carcinoma of the prostate were treated with LHRH analogue. They were divided into 3 groups according to the degree of glandular differentiation. In all groups, a transient rise of PAP and PSA was observed after the LH and testosterone surge. However, relative values of LH, testosterone, PAP and PSA did not differ significantly among the 3 groups. These facts suggest that a transient rise of PAP and PSA is caused by testosterone surge independently from the degree of glandular differentiation after LHRH analogue administration in patients with advanced prostatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fraure, N., Labrie, F., Lemay, A., Belanger, A., Gourgeau, Y., Laroche, B., Robert, G.: Inhibition of serum androgen levels by chronic intranasal and subculaneous administration of a potent luteinizing hormone releasing hormone (LHRH) agonist in adult men.Fertil. Steril., 37, 416 (1982).

    Google Scholar 

  2. Smith, J. A. Jr.: Androgen suppression by a gonadotropin releasing hormone analogue in patient with metastatic carcinoma of the prostate.J. Urol., 131, 1110 (1984).

    PubMed  Google Scholar 

  3. Kaisary, A. V., Tyrell, C. J., Peeling, W. B., Griffiths, K.: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.Br. J. Urol., 67, 502 (1991).

    Article  PubMed  CAS  Google Scholar 

  4. Winfield, H., Trachtenberg, J.: A comparison of a powerful luteinizing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer.J. Urol., 131, 1107 (1984).

    PubMed  CAS  Google Scholar 

  5. Schulze, H., Senge, T.: Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.J. Urol., 144, 934 (1990).

    PubMed  CAS  Google Scholar 

  6. Kuhn, J. M., Billerbaud, T., Navratil, H., Moulonguest, A., Fiet, J., Grise, P., Louis, J. F., Costa, P., Husson, J. M., Dahan, R., Bertagna, C., Edelstein, R.: Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostate carcinoma by administration of an antiandrogen (nilutamide).N. Engl. J. Med., 321, 413 (1989).

    Article  PubMed  CAS  Google Scholar 

  7. Schroder, F. H.: What is new in endocrine therapy of prostate cancer?Prog. Clin. Biol. Res., 357, 45 (1990).

    PubMed  CAS  Google Scholar 

  8. Soloway, M. S.: Newer methods of hormonal therapy for prostate cancer.Urology, 24, 30 (1984).

    PubMed  CAS  Google Scholar 

  9. Gleason, D. F.: Classification of prostatic carcinoma.Cancer Chemother. Rep., 50, 125 (1966).

    PubMed  CAS  Google Scholar 

  10. Zungri, E., Salvador, J., Chechile, G., Diaz, I., Martinez, E.: Delayed hormonal therapy in advanced prostatic cancer.Prog. Clin. Biol. Res., 243B 441 (1987).

    PubMed  CAS  Google Scholar 

  11. Stamey, T. A., McNeal, J. E.: Adenocarcinoma of the prostate, In: Walsh, P. C., Retik, A. B., Stamey, T. A., Vaughan, E. D. Jr. (eds): Campbell's Urology, 6th ed. Vol. 2. Chapt. 29. Saunders, Philadelphia 1992, 1159 pp.

    Google Scholar 

  12. Arai, Y., Yoshiki, T., Okada, K., Yoshida, O.: Multiple marker evaluation in prostatic cancer using prostatic specific antigen gamma-seminoprotein and prostatic acid phosphatase.Urol. Int., 44, 135 (1989).

    Article  PubMed  CAS  Google Scholar 

  13. Gleave, M. F., Hsieh, J. T., Wu, H. C., von Eschenbach, A. C., Chung, L. W. K.: Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.Cancer Res., 52, 1598 (1992).

    PubMed  CAS  Google Scholar 

  14. Weber, J. P., Oesterling, J. E., Peters, C. A., Partin, A. W., Chan, D. W., Walsh, P. C.: The influence of reversible androgen deprivation on serum prostatic-specific antigen levels in men with benign prostatic hyperplasia.J. Urol., 141, 987 (1989).

    PubMed  CAS  Google Scholar 

  15. Jackson, J. A., Waxman, J., Spiekerman, A. M.: Prostatic complications of testosterone replacement therapy.Arch. Intern. Med., 149, 2356 (1989).

    Article  Google Scholar 

  16. Lin, M. F., Davolie, J., Garcia-Arenas, R.: Expression of uman prostatic acid phosphatase activity and the growth of prostatic carcinoma cells.Cancer Res., 52, 4600 (1992).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Yamagata University, School of Medicine, Yamagata, Japan

    I. Sasagawa, T. Nakada, Y. Kubota, T. Sawamura & K. Izumiya

Authors
  1. I. Sasagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Nakada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Kubota
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Sawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Izumiya
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sasagawa, I., Nakada, T., Kubota, Y. et al. Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation. International Urology and Nephrology 27, 769–774 (1995). https://doi.org/10.1007/BF02552145

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02552145

Keywords

Search

Navigation